Palisade Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Palisade Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,890	Closed	-$698K	–	450
2016 Q4	$698K	Buy	7,890 +390	+5%	+$35.5K	0.03%	363
2016 Q3	$724K	Buy	+7,500	New	+$713K	0.03%	457
2016 Q1	–	Sell	-3,000	Closed	-$338K	–	540
2015 Q4	$338K	Buy	+3,000	New	+$326K	0.01%	485

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Palisade Capital Management's IBB Position: Q1 2017 in Review

Palisade Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 7,890 shares — an estimated $698K sold.

Palisade Capital Management first reported a position in IBB in Q4 2015 and held it in 3 quarters. The position peaked at $724K in Q3 2016. 520 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

Palisade Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
Palisade Capital Management sold 7,890 iShares Biotechnology ETF shares in Q1 2017, an estimated $698K.
Palisade Capital Management first reported a position in iShares Biotechnology ETF in Q4 2015 and held it in 3 quarters.
Palisade Capital Management's iShares Biotechnology ETF position peaked at $724K in Q3 2016.
520 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Palisade Capital Management's 13F filing for Q1 2017, filed 19 Apr 2017.